<DOC>
	<DOCNO>NCT03070782</DOCNO>
	<brief_summary>This multicenter , randomize , double-blind , placebo-controlled , dose-ranging study evaluate safety , include tolerability , ISIS 681257 ass efficacy different dos dose regimen ISIS 681257 reduction plasma Lp ( ) level patient hyperlipoproteinemia ( ) establish cardiovascular disease ( CVD ) .</brief_summary>
	<brief_title>Phase 2 Study ISIS 681257 ( AKCEA-APO ( ) -LRx ) Patients With Hyperlipoproteinemia ( ) Cardiovascular Disease</brief_title>
	<detailed_description />
	<mesh_term>Cardiovascular Diseases</mesh_term>
	<mesh_term>Hyperlipoproteinemias</mesh_term>
	<criteria>Key Clinical diagnosis CVD define documented coronary artery disease , stroke , peripheral artery disease Lp ( ) plasma level â‰¥ 60 mg/dL Must standardofcare preventative therapy elevate Lp ( ) CVD risk factor Key Within 6 month Screening : acute coronary syndrome , major cardiac surgery , stroke/TIA Within 3 month Screening : coronary , carotid , peripheral arterial revascularization , major noncardiac surgery , lipoprotein apheresis Heart failure New York Heart Association ( NYHA ) class IV</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>IONIS-APO ( ) -LRx</keyword>
	<keyword>AKCEA-APO ( ) -LRx</keyword>
</DOC>